EHA 2021 – Curis’s renaissance continues
Results in a handful of patients raise hopes again for Curis's blood cancer project CA-4948, but it is still early days.
Abingworth taps biopharma’s appetite for risk-sharing
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
Toxicity concerns send Larimar down
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Europe’s venture boom trails the US
But financing sizes have grown by a similar amount on both sides of the Atlantic.
Spac sparkle wins over health techs
Large numbers of blank-cheque groups are seeking deals, but the bloom might be coming off the rose.
Esker joins the Tyk2 race
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
